R-Bio

rBIO is a private, preclinical-stage biotech company aiming to disrupt the insulin market and bolster U.S. pharmaceutical supply chain resilience. Its core asset is a synthetic biology platform that reprograms microorganisms to produce therapeutic peptides, reportedly achieving double the insulin yield of traditional recombinant methods. The company's lead candidate, R-biolin, has demonstrated bioequivalence to Novolin R in preclinical studies and is being prepared for clinical trials and scale-up. rBIO's mission combines economic and national security objectives by targeting affordable drug production through domestic manufacturing.

A proprietary synthetic biology platform that reprograms microorganisms to produce therapeutic polypeptides. It uses novel expression controls to achieve more than double the insulin yield of traditional recombinant methods and is designed to be modular, scalable, and adaptable to different molecules and hosts.

rBIO competes in the insulin market against dominant players Eli Lilly, Novo Nordisk, and Sanofi, who control the vast majority of sales and have recently reduced list prices. It also enters the broader biosimilars arena against large generics companies and biotech firms. Its key differentiator is the combination of a high-yield synthetic biology platform and a domestic manufacturing strategy focused on supply chain resilience.